Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of “Hold” from Brokerages

Theravance Biopharma, Inc. (NASDAQ:TBPH) has been assigned a consensus rating of “Hold” from the five ratings firms that are currently covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $13.75.

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Theravance Biopharma in a research report on Monday, September 16th.

Insider Transactions at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now directly owns 322,743 shares of the company’s stock, valued at $2,904,687. This represents a 1.22 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD increased its stake in shares of Theravance Biopharma by 7.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 49,475 shares of the biopharmaceutical company’s stock valued at $444,000 after purchasing an additional 3,532 shares in the last quarter. Los Angeles Capital Management LLC purchased a new stake in shares of Theravance Biopharma in the 2nd quarter worth approximately $286,000. American Century Companies Inc. increased its position in Theravance Biopharma by 11.7% during the 2nd quarter. American Century Companies Inc. now owns 57,611 shares of the biopharmaceutical company’s stock valued at $489,000 after buying an additional 6,026 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Theravance Biopharma by 38.4% during the second quarter. Dimensional Fund Advisors LP now owns 330,181 shares of the biopharmaceutical company’s stock valued at $2,800,000 after buying an additional 91,679 shares during the last quarter. Finally, Hsbc Holdings PLC bought a new stake in Theravance Biopharma in the second quarter worth $108,000. 99.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Price Performance

NASDAQ TBPH opened at $9.88 on Monday. Theravance Biopharma has a 1 year low of $7.44 and a 1 year high of $11.71. The stock has a market capitalization of $485.84 million, a PE ratio of -9.78 and a beta of 0.23. The business’s 50-day moving average is $8.86 and its 200 day moving average is $8.72.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). The business had revenue of $16.87 million during the quarter, compared to the consensus estimate of $16.11 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. During the same quarter in the prior year, the business posted ($0.17) earnings per share. As a group, equities research analysts anticipate that Theravance Biopharma will post -1.09 earnings per share for the current year.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.